Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1,54 USD | -1,28 % | -.--% | +79,28 % |
Resumen de negocios
Número de empleados: 138
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 02/03/15 |
William Rieflin
CHM | Chairman | 64 | 01/09/10 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/08 |
William Chang
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/19 |
Hsiao Lieu
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/03/19 |
Valerie Pierce
CMP | Compliance Officer | 61 | 29/10/19 |
David Goeddel
BRD | Director/Board Member | 72 | 01/01/08 |
Joyce Q. Acbay
LAW | General Counsel | - | 01/04/20 |
Irene Perlich
AUD | Comptroller/Controller/Auditor | - | 01/03/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 08/06/21 |
David Goeddel
BRD | Director/Board Member | 72 | 01/01/08 |
William Rieflin
CHM | Chairman | 64 | 01/09/10 |
David Woodhouse
CEO | Chief Executive Officer | 54 | 02/03/15 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 83 462 408 | 81 886 322 ( 98,11 %) | 0 | 98,11 % |
Información de la empresa
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
94080-7014, South San Francisco
+650 243 5555
http://www.ngmbio.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+79,28 % | 129 M | |
-1,43 % | 104 mil M | |
+8,96 % | 105 mil M | |
+4,40 % | 22,94 mil M | |
-12,15 % | 22,34 mil M | |
-4,36 % | 19,25 mil M | |
-39,98 % | 17,08 mil M | |
-10,04 % | 16,96 mil M | |
+6,79 % | 14,16 mil M | |
+38,61 % | 12,63 mil M |
- Bolsa de valores
- Acciones
- Acción NGM
- Empresa NGM Biopharmaceuticals, Inc.